Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Price Target of $38.57

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $38.57.

A number of research analysts recently weighed in on SPTX shares. Weiss Ratings lowered shares of Seaport Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. JonesTrading started coverage on shares of Seaport Therapeutics in a research report on Wednesday, August 26th. They issued a “buy” rating and a $32.00 price objective for the company. Wolfe Research started coverage on shares of Seaport Therapeutics in a research note on Tuesday, July 7th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Seaport Therapeutics in a research report on Thursday, September 10th. Finally, Seaport Research Partners set a $46.00 target price on Seaport Therapeutics in a research note on Friday, September 25th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SPTX. TRV GP VI LLC bought a new position in Seaport Therapeutics in the 2nd quarter valued at $44,769,742. Braidwell LP purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth about $10,860,000. Citadel Advisors LLC purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth about $4,152,000. The Manufacturers Life Insurance Company purchased a new position in shares of Seaport Therapeutics in the 2nd quarter worth about $1,793,000. Finally, Alyeska Investment Group L.P. bought a new position in Seaport Therapeutics during the second quarter valued at about $1,629,000.

Seaport Therapeutics Price Performance

NASDAQ SPTX opened at $18.42 on Monday. The stock has a market cap of $986.02 million and a price-to-earnings ratio of -1.52. The company has a fifty day moving average of $22.67. Seaport Therapeutics has a 12 month low of $14.85 and a 12 month high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). As a group, research analysts anticipate that Seaport Therapeutics will post -4.52 EPS for the current fiscal year.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric and neurological disorders. The company’s research emphasizes therapies that modulate the brain’s GABAergic system, which plays an important role in mood, anxiety, and other central nervous system functions.

Seaport’s drug-development programs are based on its Glyph platform, a technology designed to improve the delivery of small-molecule medicines to the brain and enable oral versions of therapies that may otherwise require intravenous or other forms of administration.